Stay updated on NasoVAX in Early COVID-19 Clinical Trial
Sign up to get notified when there's something new on the NasoVAX in Early COVID-19 Clinical Trial page.

Latest updates to the NasoVAX in Early COVID-19 Clinical Trial page
- Check6 days agoChange DetectedFooter revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page shows a new Revision: v3.4.2 label and removal of a government funding status notice; neither affects the core study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedThe page now includes a funding-status notice and an operation-status link at the top, and the revision tag was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a 'Show glossary' option to the page and updated the QC status label to 'Last Update Submitted that Met QC Criteria'. Standardized the 'No FEAR Act Data' capitalization and updated the page revision to v3.4.0 (from v3.3.4).SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no substantive content changes to study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedThe per-state 'X Locations' headers have been replaced with a consolidated 'Locations' section listing Florida, Georgia, Illinois, North Carolina, and Texas. This update, part of revision v3.3.3, changes the layout and presentation of site locations.SummaryDifference0.7%

Stay in the know with updates to NasoVAX in Early COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NasoVAX in Early COVID-19 Clinical Trial page.